|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Vii_V_Healthcare
|
|
gptkbp:approves
|
gptkb:2019
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Dovato
|
|
gptkbp:class
|
gptkb:nucleoside_reverse_transcriptase_inhibitor
integrase inhibitor
|
|
gptkbp:clinical_trial
|
Phase III
first-line therapy
switch therapy
|
|
gptkbp:contains
|
gptkb:abacavir
dolutegravir
|
|
gptkbp:contraindication
|
gptkb:HLA-B*5701_allele
|
|
gptkbp:dosage_form
|
gptkb:tablet
gptkb:battle
|
|
gptkbp:formulation
|
oral tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dovato
|
|
gptkbp:indication
|
HIV-1 infection
|
|
gptkbp:ingredients
|
gptkb:abacavir
dolutegravir
|
|
gptkbp:interacts_with
|
gptkb:carbamazepine
gptkb:rifampin
gptkb:metformin
|
|
gptkbp:is_monitored_by
|
liver function tests
viral load
C D4 count
|
|
gptkbp:is_used_for
|
treatment of HIV
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Vii_V_Healthcare
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:pharmacokinetics
|
long half-life
high bioavailability
|
|
gptkbp:population
|
adults
pediatric patients
|
|
gptkbp:previous_name
|
gptkb:battle
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_information_on
|
once daily
|
|
gptkbp:requires
|
gptkb:battle
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
insomnia
lactic acidosis
renal impairment
hepatotoxicity
hypersensitivity reaction
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of_care
|
important for efficacy
|